BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. [electronic resource]
Producer: 20150302Description: 5074-84 p. digitalISSN:- 1558-8238
- Antineoplastic Agents -- adverse effects
- Cell Line, Tumor
- Cell Proliferation
- Cell Survival -- drug effects
- Extracellular Signal-Regulated MAP Kinases -- metabolism
- Humans
- Indoles -- adverse effects
- Intracellular Signaling Peptides and Proteins -- antagonists & inhibitors
- Leukemia, Lymphocytic, Chronic, B-Cell -- chemically induced
- MAP Kinase Signaling System
- Melanoma -- drug therapy
- Middle Aged
- Mutation, Missense
- Phosphorylation
- Protein Processing, Post-Translational
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Radionuclide Imaging
- Skin Neoplasms -- drug therapy
- Sulfonamides -- adverse effects
- Syk Kinase
- Treatment Outcome
- Vemurafenib
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.